June 2nd 2024
The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
FDA advisory impacts treatment practice patterns for atopic dermatitis in babies
October 1st 2007A retrospective, longitudinal cohort study was undertaken to analyze the effects of the FDA advisory on off-label topical calcineurin inhibitor (TCI) treatment practice patterns for infants with atopic dermatitis (<2 years of age). The results show a reduction in overall utilization of AD-related medications and reduced utilization of TCIs coupled with early introduction of topical corticosteroid treatment after the advisory compared to the period preceding the advisory.
FDA issues new warning on asthma drug Xolair
March 5th 2007Washington - The Food and Drug Administration (FDA) has issued a new warning about omalizumab, an asthma drug marketed by Genentech as Xolair, and has requested that the manufacturer add “black box” warnings to the product’s label reflecting the risk of anaphylaxis.
'Active' moisturizers key to happier skin
March 1st 2007Pittsburgh - New "activated" moisturizers help the skin retain moisture, and they also repair abnormalities with the skin at baseline in atopic dermatitis patients, according to Douglas W. Kress, M.D., of Children's Dermatology Services at Children's Hospital of Pittsburgh.
Stiefel acquisition marries technology, marketing
March 1st 2007Coral Gables, Fla. - Stiefel Laboratories' recent purchase of Connetics blends Connetics' innovative vehicle technology with Stiefel's worldwide marketing reach, company officials say. For dermatologists and patients, the acquisition augurs a steady stream of new applications for vehicles including the popular, patient-friendly foam pioneered by Connetics.
New drugs' OK process lengthy, costly
February 1st 2007National report - The Food and Drug Administration's role is a necessary one, dermatologists say, but regulatory red tape can slow the introduction of new drugs into the marketplace, and post-marketing restrictions can hamper efforts to deliver effective medications to patients.
'Fishy' symptoms should spur referral
February 1st 2007Omaha, Neb. - A patient presenting to a primary care physician with complaints of an arm rash may not be particularly unusual, but one unusual case illustrates the need for proactive cooperation between primary care physicians and specialists to best serve the patient's needs.
Be aware of lidocaine allergic contact dermatitis
February 1st 2007National report - As use of lidocaine for injectable local and topical anesthesia is increasing, dermatologists need to recognize that this amide anesthetic has the potential to cause allergic contact dermatitis, according to James Taylor, M.D., a dermatologist at The Cleveland Clinic Foundation, Cleveland.
French researchers suggest link between infant phototherapy and childhood skin moles
January 9th 2007Paris - According to a French study reported in the December issue of Archives of Dermatology, infants who received phototherapy for jaundice appear to have an increased risk of developing skin moles in childhood.